MODIFICATION OF EXTRACORPOREAL PHOTOPHERISIS TECHNOLOGY WITH PORPHYRIN PRECURSORS

摘要

The present invention relates to the use of a photoactivatable Porphyrin-Derivative in extracorporeal photophoresis (ECP) treatment, in which a patient's blood of part of it containing said Porphyrin-derivative is/are exposed to light of a wavelength which activates said photoactivatable Porphyrin-Derivative.

主权项

1. A method of extracorporeal photophoresis treatment of a patient's blood or part of such blood which comprises the blood or part thereof with an ALA-Compound which is a 5-aminolevulinic acid or an ester thereof or a salt of said acid or ester and exposing such blood or part to light of a wavelength of between and including 315 nm and 450 nm,
wherein said extracorporeal photophoresis treatment is for the treatment of cancer, lymphocyte-mediated malignant and non-malignant disorders, T-Cell-mediated diseases, autoimmune diseases or for modulating an immunological response against malignancies and immunological diseases.